Familial MRI Screening (FaMRIsc) Study group, Geuzinge, H. A., Obdeijn, I-M., Rutgers, E. J. T., Saadatmand, S., Mann, R. M., Oosterwijk, J. C., Tollenaar, R. A. E. M., de Roy van Zuidewijn, D. B. W., Lobbes, M. B. I., van 't Riet, M., Hooning, M. J., Ausems, M. G. E. M., Loo, C. E., Wesseling, J., Luiten, E. J. T., Zonderland, H. M., Verhoef, C., Heijnsdijk, E. A. M., ... de Koning, H. J. (2020). Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk. JAMA oncology, 6(9), 1381-1389. https://doi.org/10.1001/jamaoncol.2020.2922

Rovers, K. P., Bakkers, C., van Erning, F. N., Burger, J. W. A., Nienhuijs, S. W., Simkens, G. A. A. M., Creemers, G-J. M., Hemmer, P. H. J., Punt, C. J. A., Lemmens, V. E. P. P., Tanis, P. J., & de Hingh, I. H. J. T. (2020). Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases. JAMA oncology, 6(8), [202701]. https://doi.org/10.1001/jamaoncol.2020.2701

Steenbruggen, T. G., Steggink, L. C., & Sonke, G. S. (2020). High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer-Reply. JAMA oncology, 6(8), 1299-1300. https://doi.org/10.1001/jamaoncol.2020.1649

Steenbruggen, T. G., Steggink, L. C., Seynaeve, C. M., van der Hoeven, J. J. M., Hooning, M. J., Jager, A., Konings, I. R., Kroep, J. R., Smit, W. M., Tjan-Heijnen, V. C. G., van der Wall, E., Bins, A. D., Linn, S. C., Schaapveld, M., Jacobse, J. N., van Leeuwen, F. E., Schröder, C. P., van Tinteren, H., de Vries, E. G. E., ... Gietema, J. A. (2020). High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes 20-Year Follow-up of a Phase 3 Randomized Clinical Trial: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial. JAMA oncology, 6(4), 528-534. https://doi.org/10.1001/jamaoncol.2019.6276

Dafni, U., Cherny, N. I., & de Vries, E. G. E. (2019). Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Relative Clinical Survival Benefit. JAMA oncology, 5(12), 1807. https://doi.org/10.1001/jamaoncol.2019.4091

Global Burden of Disease Cancer Collaboration (2019). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA oncology, 5(12), 1749-1768. https://doi.org/10.1001/jamaoncol.2019.2996

DCOG LATER Study Grp, Kok, J. L., Teepen, J. C., van der Pal, H. J., van Leeuwen, F. E., Tissing, W. J. E., Neggers, S. J. C. M. M., Loonen, J. J., Louwerens, M., Versluys, B., van den Heuvel-Eibrink, M., van Dulmen-den Broeder, E., Jaspers, M. M. W., van Santen, H. M., van der Heiden-van der Loo, M., Janssens, G. O., Maduro, J. H., Bruggink, A. H., Jongmans, M. C., ... Ronckers, C. M. (2019). Incidence of and Risk Factors for Histologically Confirmed Solid Benign Tumors Among Long-term Survivors of Childhood Cancer. JAMA oncology, 5(5), 671-680. https://doi.org/10.1001/jamaoncol.2018.6862

Bex, A., Mulders, P., Jewett, M., Wagstaff, J., Van Thienen, J. V., Blank, C. U., Van Velthoven, R., Del Pilar Laguna, M., Wood, L., Van Melick, H. H. E., Aarts, M. J., Lattouf, J. B., Powles, T., De Jong, I. J., Rottey, S., Tombal, B., Marreaud, S., Collette, S., Collette, L., & Haanen, J. (2019). Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA oncology, 5(2), 164-170. https://doi.org/10.1001/jamaoncol.2018.5543

Targeted Alpha Therapy Working Grp, Parker, C., Lewington, V., Shore, N., Kratochwil, C., Levy, M., Linden, O., Noordzij, W., Park, J., & Saad, F. (2018). Targeted Alpha Therapy, an Emerging Class of Cancer Agents A Review. JAMA Oncol, 4(12), 1765-1772. https://doi.org/10.1001/jamaoncol.2018.4044

Global Burden of Disease Cancer Collaboration (2018). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA oncology, 1553-1568. https://doi.org/10.1001/jamaoncol.2018.2706

European Society for Medical Oncology Magnitude of Clinical Benefit Scale Working Group (2018). Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework. JAMA oncology, 4(10), 1437. https://doi.org/10.1001/jamaoncol.2018.3264

Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., Jakovljevic, M., Khader, Y., Linn, S., Lad, D., Mantovani, L., Vuong Minh Nong, Mokdad, A., Naghavi, M., Postma, M., ... Fitzmaurice, C. (2018). Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016. JAMA oncology, 4(9), 1221-1227. https://doi.org/10.1001/jamaoncol.2018.2128

de Vries, E. E. G. (2018). Refusing to Become a "Potted Plant". JAMA oncology, 4(8), 1047-1048. https://doi.org/10.1001/jamaoncol.2017.5833

Boekhout, A. H., Gietema, J. A., Kerklaan, B. M., van werkhoven, E. D., Altena, R., Honkoop, A., Los, M., Smit, W. M., Nieboer, P., Smorenburg, C. H., Mandigers, C. M. P. W., van der Wouw, A. J., Kessels, L., van der Velden, A. W. G., Ottevanger, P. B., Smilde, T., de Boer, J., van Veldhuisen, D. J., Kema, I. P., ... Schellens, J. H. M. (2016). Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. JAMA oncology, 2(8), 1030-1037. https://doi.org/10.1001/jamaoncol.2016.1726

Mohamadkhani, A., Naderi, E., Sharafkhah, M., Fazli, H. R., Moradzadeh, M., & Pourshams, A. (2013). Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer. JAMA oncology, 2013, [738915]. https://doi.org/10.1155/2013/738915